Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amikacin Sulfate

FDA-approved product (injectable, injection), marketed as Amikacin Sulfate, Amikacin Sulfate In Sodium Chloride 0.9% In Plastic Container, Amikin and 2 more.

Registered studies
50+
Lab records
133
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Amikacin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection
  • Infection
  • Infectious meningitis
  • Lung disease
  • Peritonitis
  • Respiratory tract infectious disorder
  • Sepsis
  • Staphylococcus aureus infection
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibiotics for topical use; Other aminoglycosides; Antibiotics
FDA pharmacologic class
Aminoglycoside Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB06; WHO ATC D06AX12; WHO ATC S01AA21; FDA class Aminoglycoside Antibacterial

Repurposing investigation

Amikacin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae84.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis88.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 6 of 8 lab records
  • K. pneumoniae: measured active in 73 of 115 lab records
  • M. tuberculosis: measured active in 9 of 9 lab records
Open Amikacin Sulfate in ChEMBL Registered studies below
Show the 133 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amikacin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

    NCT07485010 · start 2027-04

    Registered record
    Registry ID
    NCT07485010
    Conditions
    Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    Interventions
    Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin; clarithromycin; Clofazimine; Ethambutol; Amikacin Injection; tigecycline; Imipenem + Cilastatin; Cefoxitin; Amikacin (Inhalation); linezolid; Trimethoprim / Sulfamethoxazole; Doxycycline; moxifloxacin; bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2031-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    InterventionSulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin +14 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Inhaled Amikacin Versus Placebo in Patients With Ventilator-associated Tracheobronchitis

    NCT07665788 · start 2026-06-01

    Registered record
    Registry ID
    NCT07665788
    Conditions
    Ventilator-Associated Pneumonia; Ventilator-Associated Tracheobronchitis
    Interventions
    Optimized and protocolized nebulization procedure.; Optimized and protocolized nebulization procedure.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2029-09-01
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator-Associated Pneumonia; Ventilator-Associated Tracheobronchitis
    InterventionOptimized and protocolized nebulization procedure.; Optimized and protocolized nebulization procedure.
    PhasePhase 3
    Registry statusNot yet recruiting

  • Efficacy and Safety of Bronchoscopic Local Amikacin Instillation for Acute Exacerbations of Bronchiectasis in Adults: A Multicenter, Blinded, Randomized Controlled Trial

    NCT07813299 · start 2026-05-15

    Registered record
    Registry ID
    NCT07813299
    Conditions
    Bronchiectasis With Acute Exacerbation
    Interventions
    Bronchoalveolar Lavage and Local Amikacin Injection; Bronchoalveolar Lavage
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-05-15
    Completion
    2028-05-15
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis With Acute Exacerbation
    InterventionBronchoalveolar Lavage and Local Amikacin Injection; Bronchoalveolar Lavage
    PhaseNot applicable
    Registry statusRecruiting

  • Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care

    NCT07236944 · start 2025-12

    Registered record
    Registry ID
    NCT07236944
    Conditions
    Febrile Urinary Tract Infection
    Interventions
    Pivmecillinam; Standard of Care (Investigator Choice)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-12
    Completion
    2029-03
    Enrolment
    560

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Urinary Tract Infection
    InterventionPivmecillinam; Standard of Care (Investigator Choice)
    PhasePhase 4
    Registry statusRecruiting

  • Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

    NCT05730283 · start 2025-06-02

    Registered record
    Registry ID
    NCT05730283
    Conditions
    Ototoxicity, Drug-Induced
    Interventions
    ORC-13661; ORC-13661; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-02
    Completion
    2028-02-29
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOtotoxicity, Drug-Induced
    InterventionORC-13661; ORC-13661; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

    NCT06418711 · start 2024-09-11

    Registered record
    Registry ID
    NCT06418711
    Conditions
    MAC Lung Disease; Treatment Refractory MAC Lung Disease; Mycobacterium Infections, Nontuberculous
    Interventions
    Clofazimine Inhalation Suspension; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2024-09-11
    Completion
    2025-11-10
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMAC Lung Disease; Treatment Refractory MAC Lung Disease; Mycobacterium Infections, Nontuberculous
    InterventionClofazimine Inhalation Suspension; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients

    NCT06261164 · start 2024-01-31

    Registered record
    Registry ID
    NCT06261164
    Conditions
    Sepsis
    Interventions
    Cytosorb® and Oxiris® adsorbents
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-01-31
    Completion
    2025-01-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionCytosorb® and Oxiris® adsorbents
    PhaseNot recorded
    Registry statusUnknown

  • Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis

    NCT05761405 · start 2024-01-16

    Registered record
    Registry ID
    NCT05761405
    Conditions
    Urinary Tract Infections; Urological System Complication of Procedure
    Interventions
    mannitol-enhanced aminoglycoside; Ceftriaxon; Amikacin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2024-01-16
    Completion
    2026-04-15
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Urological System Complication of Procedure
    Interventionmannitol-enhanced aminoglycoside; Ceftriaxon; Amikacin
    PhaseEarly phase 1
    Registry statusUnknown

  • Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia

    NCT07369336 · start 2024-01-05

    Registered record
    Registry ID
    NCT07369336
    Conditions
    Ventilator Associated Pneumonia ( VAP)
    Interventions
    Amikacin (Inhalation); Standard-of-Care Intravenous Antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-01-05
    Completion
    2025-09-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia ( VAP)
    InterventionAmikacin (Inhalation); Standard-of-Care Intravenous Antibiotics
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections

    NCT05929599 · start 2023-07-05

    Registered record
    Registry ID
    NCT05929599
    Conditions
    Acute Respiratory Tract Infections; Pneumonia; Respiratory Syncytial Virus (RSV)
    Interventions
    0.9% NaCl physiological saline; LiveSpo Navax
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2023-07-05
    Completion
    2025-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Tract Infections; Pneumonia; Respiratory Syncytial Virus (RSV)
    Intervention0.9% NaCl physiological saline; LiveSpo Navax
    PhaseNot applicable
    Registry statusActive not recruiting

  • Probability of Optimal Target Attainment of Amikacin in Patients With Febrile Neutropenia During Treatment for a Hematological Disorder

    NCT05689450 · start 2022-12-21

    Registered record
    Registry ID
    NCT05689450
    Conditions
    Febrile Neutropenia (FN)
    Interventions
    Data collection: Amikacin concentration
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-12-21
    Completion
    2024-02-02
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia (FN)
    InterventionData collection: Amikacin concentration
    PhaseNot recorded
    Registry statusCompleted

  • Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study

    NCT05227937 · start 2022-09-21

    Registered record
    Registry ID
    NCT05227937
    Conditions
    Urinary Tract Infections
    Interventions
    Amikacin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-09-21
    Completion
    2026-12-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionAmikacin
    PhaseNot recorded
    Registry statusRecruiting

  • Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)

    NCT05443854 · start 2022-09

    Registered record
    Registry ID
    NCT05443854
    Conditions
    Sepsis; Septic Shock; Hematologic Malignancy; Tumor; Allogeneic Stem Cell Transplantation
    Interventions
    Aminoglycosides intervention; Lack of protective isolation intervention; No systematic aminoglycosides intervention - standard arm; Protective isolation intervention - standard arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-09
    Completion
    2024-06
    Enrolment
    340

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Septic Shock; Hematologic Malignancy; Tumor +1 more
    InterventionAminoglycosides intervention; Lack of protective isolation intervention; No systematic aminoglycosides intervention - standard arm; Protective isolation intervention - standard arm
    PhasePhase 3
    Registry statusUnknown

  • Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

    NCT04948463 · start 2021-11-15

    Registered record
    Registry ID
    NCT04948463
    Conditions
    Febrile Neutropenia
    Interventions
    Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin; Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-11-15
    Completion
    2025-12-17
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionPiperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection +8 more
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

    NCT04882085 · start 2021-08-26

    Registered record
    Registry ID
    NCT04882085
    Conditions
    Urinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia; Ventilator-associated Pneumonia; Bacteremia; Intra-abdominal Infection
    Interventions
    Zavicefta, Ceftazidime-Avibactam; Best Available Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-08-26
    Completion
    2023-08-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia; Ventilator-associated Pneumonia +2 more
    InterventionZavicefta, Ceftazidime-Avibactam; Best Available Treatment
    PhasePhase 4
    Registry statusCompleted